Fidelity Investments
CBIO

Fidelity Investments’s Crescent Biopharma CBIO Stock Holding History

Fidelity Investments’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.9M Hold
4,133,514
– – ﹤0.01% 1280
2025
Q4 		$49M Buy
4,133,514
+2,718,834
+192% +$34.6M ﹤0.01% 1455
2025
Q3 		$16.8M Buy
1,414,680
+490
+0% +$6.5K ﹤0.01% 1804
2025
Q2 		$22.8M Buy
+1,414,190
New +$29.9M ﹤0.01% 1656
2024
Q2 		– Sell
-1
Closed -$201 – 5479
2024
Q1 		$201 Buy
+1
New +$299 ﹤0.01% 4918
2022
Q1 		– Sell
-10
Closed -$1K – 5176
2021
Q4 		$1K Buy
10
+3
+43% +$544 ﹤0.01% 4137
2021
Q3 		$2K Hold
7
– – ﹤0.01% 4012
2021
Q2 		$2K Hold
7
– – ﹤0.01% 3922
2021
Q1 		$2K Hold
7
– – ﹤0.01% 3719
2020
Q4 		$3K Buy
+7
New +$2.45K ﹤0.01% 3521
2020
Q3 		– Sell
-6
Closed -$2K – 3805
2020
Q2 		$2K Buy
+6
New +$1.7K ﹤0.01% 3367
2020
Q1 		– Sell
-2
Closed -$1K – 3870
2019
Q4 		$1K Sell
2
-323
-99% -$175K ﹤0.01% 3648
2019
Q3 		$140K Sell
325
-41,740
-99% -$26.8M ﹤0.01% 2689
2019
Q2 		$50.1M Buy
42,065
+3,098
+8% +$3.7M 0.01% 1217
2019
Q1 		$48.6M Buy
38,967
+3,651
+10% +$4.18M 0.01% 1231
2018
Q4 		$33.4M Sell
35,316
-2,699
-7% -$3.25M ﹤0.01% 1336
2018
Q3 		$54.7M Buy
38,015
+409
+1% +$619K 0.01% 1231
2018
Q2 		$60.7M Buy
37,606
+2,900
+8% +$4.99M 0.01% 1186
2018
Q1 		$56.3M Buy
34,706
+6,319
+22% +$13.1M 0.01% 1240
2017
Q4 		$47.7M Buy
28,387
+13,584
+92% +$18M 0.01% 1322
2017
Q3 		$20.7M Sell
14,803
-233
-2% -$274K ﹤0.01% 1683
2017
Q2 		$16.8M Buy
+15,036
New +$12.4M ﹤0.01% 1751
2016
Q1 		– Sell
-1,492
Closed -$853K – 2692
2015
Q4 		$853K Buy
1,492
+99
+7% +$65.6K ﹤0.01% 2541
2015
Q3 		$780K Buy
1,393
+1,268
+1,014% +$916K ﹤0.01% 2550
2015
Q2 		$100K Buy
+125
New +$103K ﹤0.01% 2708

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Fidelity Investments's CBIO Position: Q1 2026 in Review

Fidelity Investments held its Crescent Biopharma (CBIO) position steady in Q1 2026 at 4,133,514 shares worth $75.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1280.

Fidelity Investments first reported a position in CBIO in Q2 2015 and has held it in 25 quarters since. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Fidelity Investments held 4,133,514 shares of Crescent Biopharma worth $75.9M as of Q1 2026.
  • Fidelity Investments left its Crescent Biopharma share count unchanged in Q1 2026.
  • Crescent Biopharma made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1280 holding.
  • Fidelity Investments first reported a position in Crescent Biopharma in Q2 2015 and has held it in 25 quarters since.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.